Maze Therapeutics, Inc. 4

Courtney Phillips, GC and Corporate Secretary of Maze Therapeutics (MAZE), sold 3,993 shares of common stock for tax withholding purposes following RSU vesting, leaving 7,007 shares owned directly.

On September 2 and 3, 2026, Courtney Phillips, GC and Corporate Secretary of Maze Therapeutics, Inc., sold a total of 3,993 shares of the company’s common stock in a series of broker transactions at weighted average prices between approximately $25.78 and $27.12 per share, explicitly to satisfy tax withholding obligations arising from the vesting of restricted stock units. The sales, which are characterized in the footnotes as tax-related and not discretionary open‑market liquidations, reduced Phillips’s directly held position to 7,007 shares of common stock following the final transaction. While the aggregate dollar value of the dispositions is modest, these transactions are structurally routine in nature and tied to equity compensation rather than an independent investment decision, limiting their negative signaling value.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0001782758-26-000008

Alert Tier

5